RxDoctor Payments DataLook up a doctor →

Chandni Patel

Nurse Practitioner · Middletown, DENPI 1790322345

Payments from drug & device makers

$112,829in general payments, 2019–2025

Across 611 payments — averaging $184.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$89K
  • Arcutis Biotherapeutics, Inc.$8K
  • Regeneron Healthcare Solutions, Inc.$7K
  • AbbVie$4K
  • Sanofi$687
  • UCB, Inc.$511
  • plus $4K from 26 others

What the payments were for

  • Consulting fees$14,57513%
  • Speaking & faculty fees$71,49463%
  • Travel & lodging$13,75912%
  • Food & beverage$11,88211%
  • Education$1,1201%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$112,829 in reported general payments places this provider in the 95th percentile of 487 nurse practitioner providers in Delaware.

See all nurse practitioner providers in Delaware

Medicare billing

Part B allowed, 2024
$151,599
Medicare patients
776
Services billed
2,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab68$304,942
TremfyaGuselkumab17$215,198
Clobetasol Propionate49$3,723
Ketoconazole107$1,979
Triamcinolone Acetonide90$836
Metronidazole15$751
Clindamycin Phosphate16$686
Nystatin34$520
Mupirocin67$506
NyamycNystatin19$359
NystopNystatin13$301
Hydrocortisone28$263
Mometasone Furoate12$261
Doxycycline Hyclate11$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$89,031$215,19817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 487 nurse practitioner providers in Delaware.

Other nurse practitioner in Middletown

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →